Eneboparatide
Peptide
Also known as AZP-3601
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook · registrational
Hypoparathyroidism: registrational readout pending
Its supporting mid-stage studies have completed. The registry records primary completion on 2024-11-15; results are not yet reported. Check News for topline announcements.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Hypoparathyroidism: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Eneboparatide: this drug | Phase 3 | Peptide | Parathyroid hormone receptor 1 (PTH1R) | not yet graded | No reviewed efficacy summary in this indication | |
| Palopegteriparatide (Yorvipath) | Approved | Peptide | PTH1 receptor (PTH replacement) | Reliable signal | NCT04701203: Efficacy - Primary Endpoint During the Blinded Period (26 weeks): TransCon PTH 78.7 Percentage of participants (95% CI 66.3 to 88.1) | Placebo 4.8 Percentage of participants (95% CI 0.1 to 23.8) |
Upcoming events
No upcoming readouts on record for this asset.